Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein.
about
A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitorRifampicin alters the expression of reference genes used to normalize real-time quantitative RT-PCR data.Eg5 inhibitor, a novel potent targeted therapy, induces cell apoptosis in renal cell carcinoma.A Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder Cancer.Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions.Impact of enzalutamide and its main metabolite N-desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters.Differential effects of the enantiomers of tamsulosin and tolterodine on P-glycoprotein and cytochrome P450 3A4.Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines.Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters.In-vitro evaluation of chronic alcohol effects on expression of drug-metabolizing and drug-transporting proteins.Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro.Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro.A good molecular target for prostate cancer chemotherapy.Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactionsInteraction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolising enzymes assessed in vitro.Pre-clinical pharmacokinetics and acute toxicological evaluation of a monastrol derivative anticancer candidate LaSOM 65 in rats.
P2860
Q33812795-43B3FF2F-639C-4510-912E-B17403350787Q34349015-AC47E683-0742-408D-B40D-CDC5ECB12BF1Q35163926-C419C1AC-E7DC-4807-AAA7-55D4DB15C726Q35866655-487925EE-3B19-4E65-A597-FC99F193BFFEQ36735325-D44A42E5-1183-4EDC-ADFF-65922CE37EBAQ38597025-39A5700E-A7BE-4097-90DB-6A6AC452A1C2Q38743428-64AA8127-F49B-49A1-BA14-B3AA3C660064Q38757895-A5CA5E4C-31A2-4E94-B171-4DEDB04BDCDBQ38845179-868B8627-3A2A-4472-B241-1EA2BAEB389FQ38925278-38A51043-433F-4292-9504-FE03621959F7Q38932086-12F7ABD6-9014-413E-B654-95D5F28AE483Q39096762-9063C0EC-9534-4CCF-BA31-923C6B9FDB66Q39182548-06C80717-22EF-40BE-BDA3-EC5382CEB22BQ39497283-47A34767-ED4B-41B0-B73C-D52D24A7A6F1Q39593019-CAF343F1-F572-4C78-A01E-17D814618561Q41620033-89D26AB7-EE59-47CF-AF8B-D34616495444Q43084566-FFB36A60-5431-4D94-81E7-E18EE238A279Q43541374-EA67BB09-A825-4685-AD4E-5EB9C964A286
P2860
Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein.
@ast
Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein.
@en
type
label
Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein.
@ast
Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein.
@en
prefLabel
Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein.
@ast
Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein.
@en
P2093
P1476
Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein.
@en
P2093
Heike Lindenmaier
Johanna Weiss
Tanja Peters
Walter E Haefeli
P2888
P304
P356
10.1007/S00210-005-0022-5
P577
2005-12-20T00:00:00Z
P6179
1045737926